Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Immunotherapy · 1 trial · 3 indications
To assess the feasibility of an FDG-PET-based small volume accelerated chemoradiotherapy followed by immunotherapy with durvalumab compared to standard FDG-PET-based chemoradiotherapy followed by immunotherapy with durvalumab Completion rate defined as rate of patients having received: * the prescribed radiotherapy dose ± 2 fractions and * simultaneous platinum-based chemotherapy and · immunotherapy consolidation with durvalumab starting within 42 days after the last dose of chemoradiotherapy and * either at least 3 doses of durvalumab or less than 3 doses of durvalumab in case immunotherapy was permanently discontinued due to documented extrathoracic immune-related toxicity.
| Arm | Type | Description |
|---|---|---|
| Conventional Arm | ACTIVE_COMPARATOR | standard FDG-PET-based radiotherapy with concurrent standard of care chemotherapy |
| Experimental Arm | EXPERIMENTAL | FDG-PET-based small volume accelerated radiotherapy with concurrent standard of care chemotherapy |
| Name | Type | Description |
|---|---|---|
| standard Radiotherapy | RADIATION | standard FDG-PET-based radiotherapy |
| Chemotherapy | DRUG | concurrent standard of care chemotherapy |
| Immunotherapy | DRUG | standard of care consolidation therapy with durvalumab (fixed dose of 1500 mg q4w) for up to 12 months or until progression of disease, unacceptable toxicity, patient´s wish, or investigator´s decision, whichever comes first. |
| Experimental Radiotherapy | RADIATION | FDG-PET-based small volume accelerated radiotherapy |
Inclusion Criteria: * Written informed consent * Patients irrespective of sex and gender, aged 18 years or older at the time of signing the ICF * Patients must be willing and able to comply with scheduled visits, treatment schedule, laboratory testing, and other requirements of the study as determi...
Immunotherapy is an investigational small molecule being studied for the treatment of Stage III Non-small Cell Lung Cancer, specifically in patients with locally advanced, unresectable disease. It is currently in Phase 2 clinical development and is being evaluated as part of a combination regimen with chemo-radiotherapy.
Immunotherapy is being developed by AstraZeneca PLC, a biopharmaceutical company listed on the stock exchange under the ticker AZN. The company is conducting a Phase 2 clinical trial to evaluate this investigational treatment in patients with Stage III Non-small Cell Lung Cancer.
Immunotherapy is currently in Phase 2 clinical development. It is an investigational drug and has not yet been approved by regulatory authorities. The ongoing Phase 2 trial is actively recruiting participants to evaluate its safety and efficacy in Stage III Non-small Cell Lung Cancer.
Immunotherapy is being evaluated in a single Phase 2 clinical trial with the identifier NCT06102057. This trial, titled PACCELIO, is a randomized, active-controlled study investigating FDG-PET based small volume accelerated immuno chemoradiotherapy in locally advanced NSCLC. The trial is recruiting 110 participants in Germany and Switzerland.
Immunotherapy is a small molecule designed to modulate the immune system to fight cancer. While the specific molecular target has not been disclosed, it is being studied in combination with chemoradiotherapy to enhance the immune response against tumor cells in patients with Stage III Non-small Cell Lung Cancer.